🏛️ Verified NIH Record • Updated 2026-06-07
Troriluzole in Adult Participants With Spinocerebellar Ataxia (NCT03701399)
A Phase III, Long-Term, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Participants With Spinocerebellar Ataxia.
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Biohaven Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy of Troriluzole (200 mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).
Who can join: Review the eligibility criteria below.
Location: Barrow Neurological Institute — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (23 Sites)
- Barrow Neurological Institute — Phoenix, Arizona
- CNS Trials — Long Beach, California
- UCLA — Los Angeles, California
- UCSF — San Francisco, California
- University of Colorado Hospital — Aurora, Colorado
- University of Florida Health — Gainesville, Florida
- Mayo Clinic Florida — Jacksonville, Florida
- University of South Florida — Tampa, Florida
- Emory — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- Northwest Neurology, Ltd. — Rolling Meadows, Illinois
- Johns Hopkins Medicine — Lutherville, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Columbia University — New York, New York
- Duke University Movement Disorders Clinic — Durham, North Carolina
- University of Pennsylvania — Philadelphia, Pennsylvania
- Houston Methodist — Houston, Texas
- Swedish Health Services — Seattle, Washington
- Central South University Xiangya Hospital — Changsha, Hunan
- West China Hospital of Sichuan University — Chengdu, Sichuan
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Spinocerebellar Ataxias
- Open Pilot Trial of BHV-4157 — Los Angeles, California
- Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases — Jacksonville, Florida
- Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control — New Haven, Connecticut
Explore by condition: All Spinocerebellar Ataxias clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.